All In Biotech

Drug Trial Radar · NCT05786924

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

623

Planned (sponsor's estimate)

Start

Apr 18, 2023

Primary completion

Jun 2028

Study completion Jun 2028

Sponsor

Lead sponsor
Institut de Recherches Internationales ServierAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/metastatic non-small cell lung cancer (NSCLC), Gastrointestinal (GI) cancers, and other solid tumors harboring KRAS, HRAS, NRAS, BRAF, and/or CRAF (Rapidly Accelerated Fibrosarcoma (RAF1)) mutations or alterations. A dose optimization part in adults with NSCLC may follow the dose escalation phase if the sponsor, in consultation with the safety review committee, decides it is necessary to further characterize the optimal dose. The study population for the Dose Expansion part of the study comprises adults with advanced/metastatic NSCLC, GI tumors (including ColoRectal Cancer (CRC), and non-CRC GI adenocarcinoma, and Biliary Tract Cancer (BTC)) with KRAS, HRAS, NRAS, BRAF, or CRAF (RAF1) mutations and alterations. All patients will self-administer S241656 orally in 28 or 21-days cycles (depending on the study part they are included in) until disease progression, toxicity, withdrawal of consent, or termination of the study.

Conditions

  • Non-small Cell Lung Cancer
  • Histiocytic Neoplasm
  • Histiocytosis
  • BRAF Gene Mutation
  • BRAF V600E
  • BRAF V600 Mutation
  • BRAF Mutation-Related Tumors
  • BRAF
  • Metastatic Lung Non-Small Cell Carcinoma
  • Metastatic Lung Cancer
  • Recurrent Lung Cancer
  • Recurrent Lung Non-Small Cell Carcinoma
  • NSCLC
  • Solid Tumor
  • Solid Carcinoma
  • KRAS G12D
  • KRAS G12V
  • KRAS Mutation-Related Tumors
  • NRAS Gene Mutation
  • Thyroid Cancer
  • Thyroid Carcinoma
  • Colorectal Cancer
  • Colorectal Carcinoma
  • Recurrent Histiocytic and Dendritic Cell Neoplasm
  • Brain Metastases
  • Recurrent NSCLC
  • KRAS G13C
  • Acquired Resistance to KRAS G12C Inhibitor
  • KRAS G12A
  • KRAS G12F
  • KRAS G12R
  • KRAS G13D

Interventions

  • S241656Drug

    RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III) and constitutively active CRAF, KRAS or NRAS mutations

  • FOLFOX6/FOLFOX7Drug

    Used as a combination therapy and administered intravenously

  • FOLFIRIDrug

    Used as a combination therapy and administered intravenously

  • CetuximabDrug

    Used as a combination therapy and administered intravenously

  • PanitumumabDrug

    Used as a combination therapy and administered intravenously

  • TrametinibDrug

    Used as a combination therapy and administered orally

  • PembrolizumabDrug

    Used as a combination therapy and administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation: Incidence of dose-limiting toxicities (DLTs)Time frame: The first 28-day cycle (Cycle 1)
  2. Dose Escalation: Number of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Through study completion, approximately 5 years
  3. Dose Optimization/Expansion: Objective response (OR)Time frame: Through study completion, approximately 5 years

Locations

49 sites in 10 countries. Site status is shown where the registry gives one.

  • Banner Health- MD Anderson Cancer Center

    Gilbert, Arizona · Recruiting

  • The Angeles clinic - A cedars SINAI AFFILIATE

    Los Angeles, California · Recruiting

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • University of California, San Francisco (UCSF)

    San Francisco, California · Recruiting

  • University of Colorado - Aurora Cancer Center

    Aurora, Colorado · Not yet recruiting

  • Yale University School of Medicine - Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Georgetown University Lombardi Cancer Center

    Washington D.C., District of Columbia · Not yet recruiting

  • Sibley Memorial Hospital

    Washington D.C., District of Columbia · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • South Texas Accelerated Research Therapeutics (START) Midwest

    Grand Rapids, Michigan · Recruiting

  • Masonic Cancer Center University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute)

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Duke University School of Medicine

    Durham, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Sarah Canon Research Institute (SCRI) Oncology Partners

    Nashville, Tennessee · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • START San Antonio

    San Antonio, Texas · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington · Recruiting

  • Peter MacCallum Cancer Centre

    East Melbourne, Australia · Not yet recruiting

  • Westmead Hospital

    Westmead, Australia · Not yet recruiting

  • Beijing Cancer Hospital

    Beijing, China · Recruiting

  • Shandong Cancer Hospital (Cancer Hospital of Shandong First Medical University)

    Jinan, China · Recruiting

  • Fudan University Zhongshan Hospital

    Shanghai, China · Not yet recruiting

  • The Second Affiliated Hospital of Soochow University

    Suzhou, China · Recruiting

  • Center for Cancer and Organ Diseases - Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • Centre Georges Francois Leclerc

    Dijon, France · Not yet recruiting

  • Institut Curie

    Paris, France · Recruiting

  • AP-HP Hopital Europeen Georges Pompidou

    Paris, France · Recruiting

  • Centre Eugene Marquis

    Rennes, France · Recruiting

  • Institut Gustave Roussy

    Villejuif, France · Not yet recruiting

  • Queen Mary Hospital

    Hong Kong, Hong Kong · Recruiting

  • Prince of Wales

    Shatin, Hong Kong · Recruiting

  • Istituto Europeo di Oncologia

    Milan, Italy · Not yet recruiting

  • IFO - Istituto Nazionale dei Tumori Regina Elena

    Rome, Italy · Not yet recruiting

  • Istituto Clinico Humanitas

    Rozzano, Italy · Recruiting

  • Kanagawa Cancer Center

    Kanagawa, Japan · Recruiting

  • Kyoto University Hospital

    Kyoto, Japan · Recruiting

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.